Three Details Worth a Second Read

There are nine pieces in this issue. Three left me with something specific enough to repeat, and that is what this letter is about. Each one takes something the industry has treated as settled — a policy timeline, a price ceiling, a pricing assumption — and shows it was never as permanent as it appeared.

The first is a particularly relevant timeline problem, and it starts where the policy conversation about combination vaccines usually stops. In “One Vaccine, Three Supply Chains: The Hidden Consequences of Splitting MMR,” Thani Jambulingam, Ph.D., examines what it would actually take to split the combination MMR vaccine into three separate products, and the answer is three supply chains, three licensing pathways and manufacturing capacity that does not exist today. Policy can change in a matter of days. Capacity takes years. That gap is not a talking point. It is a scheduling constraint, and it does not negotiate.

The second comes from Robert Rouse, on what payers do with a price they can see. Medicare's Maximum Fair Price carries no statutory weight in commercial contracting. It applies where the statute says it applies and nowhere else. Payers cite it anyway, alongside direct-to-patient cash offers and most favored nation reference points, because a published number is usable in a negotiation whether or not it is binding in one. The leverage is not legal. It is informational, and it did not require anyone to pass anything.

The third is Bill Roth closing out The Great Repricing series with seven assumptions that no longer hold, including the idea that a price increase reliably grows net revenue. Rather than replace one pricing model with another, Roth maps where the discipline is actually headed: a U.S. market that now runs on three distinct payer economies, commercial, government and cash, each demanding its own pricing and channel architecture.

The pieces I did not single out are not lesser ones. They cover MFN and ex-US launches, direct-to-patient compliance, GDP logistics and real-world evidence, and each earned its place. Read together, they describe an industry adjusting to constraints it did not choose and timelines it cannot compress.

I would love to hear which articles you find yourself returning to.